IDXX · XBRL financial data

Idexx Laboratories financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (IDXX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	2,707	3,215	3,367	3,661	3,898	4,304
Cost of revenue	1,136	1,326	1,363	1,471	—	—
Cost of goods and services sold	—	—	1,363	1,471	1,519	1,644
Gross profit	1,571	1,889	2,004	2,190	2,379	2,660
Research and development	141	161	255	191	220	251
General and administrative	301	310	326	336	442	405
Total operating expenses	—	—	1,106	1,093	1,251	1,300
Operating income (loss)	695	932	899	1,097	1,128	1,360
Interest expense	33	30	40	42	31	39
Income tax expense (benefit)	80	158	181	216	222	265
Net income (loss)	582	745	679	845	888	1,059
Earnings per share, basic USD per share	6.82	8.74	8.12	10.17	10.77	13.17
Earnings per share, diluted USD per share	6.71	8.60	8.03	10.06	10.67	13.08
Weighted average shares, basic millions of shares	85	85	84	83	82	80
Weighted average shares, diluted millions of shares	87	87	85	84	83	81

Fiscal years (IDXX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	384	144	113	454	288	180
Accounts receivable	331	368	401	457	474	552
Inventory	210	269	368	380	382	378
Total current assets	1,063	956	1,101	1,495	1,400	1,414
Property and equipment, net	555	588	649	702	713	747
Right-of-use asset	91	105	119	115	116	123
Goodwill	243	359	362	366	405	414
Total assets	2,295	2,437	2,747	3,260	3,293	3,351
Accounts payable	75	116	110	111	114	110
Accrued liabilities	416	459	434	479	502	530
Current portion of long-term debt	50	75	75	75	168	75
Total current liabilities	583	764	1,236	952	1,068	1,149
Long-term debt	858	775	694	623	450	375
Lease liability, non-current	77	87	101	100	98	101
Total liabilities	1,662	1,747	2,138	1,775	1,698	1,745
Retained earnings	2,176	2,920	3,600	4,445	5,332	6,392
Total stockholders' equity	632	690	609	1,485	1,595	1,605
Total liabilities and equity	2,295	2,437	2,747	3,260	3,293	3,351
Common shares outstanding (cover page) millions of shares	85	84	83	83	81	80

Fiscal years (IDXX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	582	745	679	845	888	1,059
Stock-based compensation	31	38	50	60	60	60
Depreciation and amortization	96	105	112	115	130	145
Net cash from operating activities	648	756	543	907	929	1,182
Purchases of property and equipment	107	120	149	134	121	125
Net cash from investing activities	(109)	(293)	(195)	(125)	(207)	(136)
Share repurchases	183	747	820	72	837	1,217
Net cash from financing activities	(248)	(697)	(371)	(442)	(878)	(1,165)
Net change in cash	294	(239)	(32)	341	(166)	(108)

SIC 2835 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2835 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Quarter
Idexx Laboratories	198	1,214	450*	78.8M	Q3 FY26 10-QSep 30, 2026
Alnylam Pharmaceuticals	1,754	1,458	341*	133.9M	Q3 FY26 10-QSep 30, 2026
Regeneron Pharmaceuticals	3,659	5,116	1,783*	not reported	Q3 FY26 10-QSep 30, 2026
Zoetis	1,476	2,468	655*	413.2M	Q2 FY26 10-QJun 30, 2026
INSMED	397	524	(36)*	219.4M	Q3 FY26 10-QSep 30, 2026
Bristol Myers Squibb	9,574	13,069	4,181*	2.0B	Q3 FY26 10-QSep 30, 2026
Biogen	1,304	2,804	641*	147.8M	Q3 FY26 10-QSep 30, 2026
Teva Pharmaceutical Industries	4,085	4,395	241	1.2B	Q3 FY26 10-QSep 30, 2026
Gilead Sciences	6,437	8,300	5,035*	1.2B	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.